Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | MAS1 | P04201 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652327 | 1.00 | TP53 (0.38) | TP53GAAMAPTSMN1; SMN2GP6 | |
| SCHEMBL7614735 | 0.93 | GP6 (0.39) | GP6OPRM1OPRK1MAS1 | |
| SCHEMBL7614742 | 0.93 | GP6 (0.39) | GP6OPRM1OPRK1MAS1 | |
| SCHEMBL7648058 | 0.85 | TP53 (0.42) | TP53GAAMAPTSMN1; SMN2GP6 | |
| SCHEMBL7652325 | 0.83 | MAS1 (0.39) | TP53GAAMAPTSMN1; SMN2MAS1 | |
| SCHEMBL6231353 | 0.82 | PTGDR2 (0.36) | TP53GAASMN1; SMN2GP6MAS1 | |
| SCHEMBL6231352 | 0.82 | PTGDR2 (0.36) | TP53GAASMN1; SMN2GP6MAS1 | |
| SCHEMBL7611012 | 0.81 | GP6 (0.58) | GP6 | |
| SCHEMBL7611021 | 0.81 | GP6 (0.58) | GP6 | |
| SCHEMBL7648006 | 0.80 | MAS1 (0.39) | TP53GAAMAPTSMN1; SMN2MAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369236-B1 | DRUG FOR MEDICAL DIAGNOSIS ANTIARRHYTHMIC PROPRIETIES AND CONTAIN A CARDIOPROTECTIVE COMPOUND. THEY CAN PREVENTIVELY INHIBIT OR STRONGLY REDUCE PATHOPHYSIOLOGIC PROCESSES UPON OCCURRENCE OF ISCHEMIC INJURIES, ESPECIALLY ISCHEMIC CARDIAC | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |